Cowen Liquid Biopsy Summit

Kevin Conroy, Chairman and CEO

1

September 24, 2020

2

Safe harbor statement

Forward-Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission. Specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections of forward-looking statements.

3

Leading, global, advanced cancer diagnostics company

1,000+commercial organization

250+skilled R&D employees

4,000+employees

Headquarters Offices

$1.3B Proforma 2019 revenue*

*Includes Genomic Health revenue prior to November acquisition close

4

Steps to successfully bring new cancer screening tests to patients and physicians

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

5

Marker discovery

Systematically

identifying markers

with Mayo Clinic

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

Average accuracy of

methylation markers identified

across top cancers in tissue*

*As defined by AUC (area under the curve), a measure of both sensitivity and specificity

97%Patents filed for

discovered markers

~3,000

6

Marker discovery process

Discover markers in tissue Validate in blood Identify markers >95%

accurate in both

7

Sample collection

Banked blood

samples

Superior blood preservation

with LBGard tube*

215,000+

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

*Tube and technology acquired in Biomatrica acquisition

8

Platform technology

Sophisticated

platform well-suited

to blood testing

Differentiated DNA

extraction, PCR, &

sequencing capabilities

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

9

Clinical trials

Person trials:

DeeP-C, BLUE-C,

TAILORx, TIDAL, Voyage

Abstracts and

publications*

600+10,000+

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

*Includes Genomic Health publications prior to acquisition

FDA

10

Regulatory expertise

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

11

Insurance coverage

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

*Exact Sciences estimate based on historical patient billing and impact of recently executed network agreements

Contracted with all

major commercial

payers

Medicare &

Medicaid

coverage

>95% lives

covered*

12

Lab infrastructure

4 labs in

WI(2), CA, AZ

Square feet of

clinical lab space

230,000+

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

13

IT foundation

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

Primary care

officesPayers

Health

systems

Customer

care

Billing &

reimbursement

Data

analysis

14

Customer service

24/7Customer support

200+Languages available

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

9.3MTotal patient and provider

support calls in 2020

15

Sales and marketing strength

Sales & marketing

investment since 2009*

Person team

1,000+ $2.6B

Marker

discovery

Sample

collection

Platform

technology

Clinical

trials

Regulatory

expertise

Insurance

coverage

Lab

infrastructure

IT

foundation

Customer

service

Sales & marketing

strength

Specialties: primary care,

oncology, gastroenterology,

urology, & women’s health

5

*Includes Genomic Health investment prior to acquisition

16

Screen fewer people to detect 1 cancer with multi-cancer approach

166People need to be

screened to detect 1

colorectal cancer

~30People need to be

screened to detect 1

type of multi-cancer

166

~30

Colorectal

Multi-cancer

Sources: Imperiale TF et al., N Engl J Med (2014)

Karwinski 1990, Burton 1998, Sens 2009, Ahlquist 2017; assumes ~85% sensitivity for a multi-cancer test

17

Colorectal cancer is just the beginning – EXAS is uniquely positioned to address multi-cancer screening

Esophageal 89% (16/18)

Liver 83% (30/36)

Lung 78% (28/36)

Ovarian 90% (27/30)

Pancreatic 90% (27/30)

Stomach 87% (26/30)

87%

Training

Sensitivity 83%

Validation

Sensitivity 86% Sensitivity

Overall

Specificity

95%

Note: preliminary data from a study of 180 cases and 257 controls; validation set was 1/3 of total samples; currently evaluating whether performance is maintained

in early stage disease across additional cancers; performance degradation is typical when moving from smaller case control to larger prospective trials;

stage breakdown: 5 stage I, 43 stage II, 65 stage III, 56 stage IV, 11 un-staged

N=292120 cases

172 controls

N=14560 cases

85 controls

18

Unique capabilities will support multi-cancer screening

3,500+Cases collected

across all stages

1,400+Stages 0, I, and II

Note: only includes cases collected from multi-cancer sample collection trial: ClinicalTrials.gov identifier NCT03662204

19